Scientific article
Open access

Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells

Published inCommunications Biology, vol. 4, no. 1, 718
Publication date2021

Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3high glioblastoma (GBM) tumors mainly within the mesenchymal subtype that are addicted to Gal-3-mediated macropinocytosis. Using both genetic and pharmacologic inhibition of Gal-3, we showed a significant decrease of GSC macropinocytosis activity, cell survival and invasion, in vitro and in vivo. Mechanistically, we demonstrate that Gal-3 binds to RAB10, a member of the RAS superfamily of small GTPases, and β1 integrin, which are both required for macropinocytosis activity and cell survival. Finally, by defining a Gal-3/macropinocytosis molecular signature, we could predict sensitivity to this dependency pathway and provide proof-of-principle for innovative therapeutic strategies to exploit this Achilles' heel for a significant and unique subset of GBM patients.

Citation (ISO format)
SEGUIN, Laetitia et al. Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. In: Communications Biology, 2021, vol. 4, n° 1, p. 718. doi: 10.1038/s42003-021-02258-z
Main files (1)
Article (Published version)
Secondary files (2)
ISSN of the journal2399-3642

Technical informations

Creation06/11/2021 1:46:00 PM
First validation06/11/2021 1:46:00 PM
Update time03/16/2023 12:44:55 AM
Status update03/16/2023 12:44:53 AM
Last indexation05/06/2024 7:43:23 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack